The growing prevalence of antibiotic-resistant bacterial pathogens and the lack of new medicines to treat the infections they cause remain a significant global threat. In recent years, this ongoing unmet need has encouraged more research groups to focus on the discovery and development of nontraditional antibacterial agents, ranging from anti-virulence strategies to bacteriophage and ways to modulate the microbiome. The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a global nonprofit public–private partnership dedicated to accelerating antibacterial-related research. Importantly, the CARB-X portfolio supports a wide variety of novel and innovative nontraditional programs to help the global antibacterial research ecosystem understand the potential that these modalities can play in the management or prevention of serious infections. We describe here the breadth of the CARB-X pipeline of novel nontraditional products.

中文翻译：

---

CARB-X 非传统抗菌产品组合

抗生素耐药性细菌病原体的日益流行以及治疗它们引起的感染的新药的缺乏仍然是一个重大的全球威胁。近年来，这种持续未满足的需求促使更多研究小组专注于非传统抗菌剂的发现和开发，从抗毒力策略到噬菌体以及调节微生物组的方法。Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) 是一个全球性的非营利性公私合作伙伴关系，致力于加速抗菌相关研究。重要的，CARB-X 产品组合支持各种新颖和创新的非传统计划，以帮助全球抗菌研究生态系统了解这些模式在管理或预防严重感染方面的潜力。我们在这里描述了新型非传统产品的 CARB-X 管道的广度。